GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

According to our calculations, a $1000 investment made in January 2015 would be worth $4,020.91, or a gain of 302.09%, as of January 27, 2025, and this return excludes dividends but includes price ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, capital equipment and services ...